Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNexus Gene LabBGLC +4.67%58 Net Current Asset Value is $1.76 as of Mar. 2026, which is 85% below its 10-year median of 11.68. GuruFocus rates BGLC with a GF Score™ of 58/100 and a GF Value™ of $2.17 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 944 Chemicals companies, BioNexus Gene Lab ranks better than 93.96% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
BioNexus Gene Lab's net current asset value per share for the quarter that ended in Mar. 2026 was $1.76.
The historical rank and industry rank for BioNexus Gene Lab's Net Current Asset Value or its related term are showing as below:
BGLC'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.88 Med: 11.68 Max: 240
Current: 0.96
During the past 8 years, the highest Price-to-Net-Current-Asset-Value Ratio of BioNexus Gene Lab was 240.00. The lowest was 0.88. And the median was 11.68.
BGLC's Price-to-Net-Current-Asset-Value is ranked better than 93.96% of 944
companies
in the Chemicals industry
Industry Median: 5.155
vs BGLC: 0.96
BioNexus Gene Lab (NAS:BGLC) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
BioNexus Gene Lab Net Current Asset Value Related Terms
BioNexus Gene Lab Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for BioNexus Gene Lab's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BGLC vs QGAI, VYST, GLGI: Net Current Asset Value Comparison
For the Specialty Chemicals subindustry, BioNexus Gene Lab's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab Price-to-Net-Current-Asset-Value vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $1.76 mean?
BioNexus Gene Lab (BGLC) has a Net Current Asset Value of $1.76 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on BioNexus Gene Lab and its competitors. This is 85% below median its historical median of 11.68. Over the past decade, BioNexus Gene Lab's Net Current Asset Value has ranged from 0.88 to 240.00. According to the industry distribution chart, BioNexus Gene Lab ranks #57 out of 944 companies in the Chemicals industry, placing it in the top 6%.
Is BioNexus Gene Lab's Net Current Asset Value too high?
BioNexus Gene Lab's current Net Current Asset Value of $1.76 is 85% below median its 10-year median of 11.68. Over the past 10 years, this metric has ranged from a low of 0.88 to a high of 240.00. The Chemicals industry median Net Current Asset Value is 5.16. BioNexus Gene Lab's value of $1.76 is 65.9% below this industry median. Based on the distribution chart, BioNexus Gene Lab ranks #57 out of 944 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, BioNexus Gene Lab has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's Net Current Asset Value compare to QGAI and VYST?
According to the Chemicals industry distribution chart, BioNexus Gene Lab ranks #57 out of 944 companies for Net Current Asset Value. This places BioNexus Gene Lab in the top 6% of its industry — outperforming the majority of peers. The industry median Net Current Asset Value is 5.16. BioNexus Gene Lab's value of $1.76 is 65.9% below this benchmark. Historically, BioNexus Gene Lab's own Net Current Asset Value has ranged from 0.88 to 240.00 over the past decade. While the company's 10-year median is 11.68 vs. the industry median of 5.16, BioNexus Gene Lab has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Chemicals company?
The median Net Current Asset Value among Chemicals companies is 5.16, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioNexus Gene Lab's current Net Current Asset Value of $1.76 is 65.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on BioNexus Gene Lab and its competitors. For the Chemicals industry, the median Net Current Asset Value is 5.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNexus Gene Lab's current Net Current Asset Value is $1.76, which is 85% below median its own 10-year median of 11.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.17, compared to a current price of $1.68 — trading 22.6% below its estimated fair value. The current Net Current Asset Value is $1.76, which is 85% below median its 10-year median of 11.68 and 65.9% below the Chemicals industry median of 5.16. BioNexus Gene Lab's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current Net Current Asset Value is $1.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNexus Gene Lab (BGLC) Overvalued in 2026?
Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be undervalued.
The current stock price of $1.68 is trading 22.6% below its estimated GF Value™ of $2.17.
GuruFocus considers BioNexus Gene Lab to be Modestly Undervalued.
Key valuation signals for BGLC:
Net Current Asset Value: $1.76 (85% below median its 10-year median of 11.68)
GF Value™: $2.17 vs. price of $1.68 (22.6% below fair value)
Industry Position: 65.9% below the Chemicals median (#57 of 944)
No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
58GF Score
Get the complete analysis for BGLC
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLC has been successfully added to your 
